KMDA Kamada

Kamada Provides Update on 2021 GLASSIA® Supply to Takeda

Kamada Provides Update on 2021 GLASSIA® Supply to Takeda
EN
07/10/2020

Underlying

KMDAKamada

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Kamada

 PRESS RELEASE
Free
KMDA KAMADA

Kamada to Participate in Upcoming September Investor Conferences

Kamada to Participate in Upcoming September Investor Conferences REHOVOT, Israel, and HOBOKEN, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that Amir London, Chief Executive Officer, will participate in the 2025 Wells Fargo Healthcare Conference and the H.C. Wainwright 27th Annual Global Investment Conference. Mr. London is scheduled to present at the 2025 Wells Fargo...

September 2, 2025 1 EN
 PRESS RELEASE
Free
KMDA KAMADA

Kamada Reports Strong Second Quarter and First Half 2025 Financial Res...

Kamada Reports Strong Second Quarter and First Half 2025 Financial Results with 11% Year-Over-Year 6-Month Top Line Growth and a 35% Increase in Profitability; Raises Full-Year Profitability Guidance First Half 2025 Total Revenues were $88.8 Million, up 11% Year-over-Year; Revenues for 2025 Second Quarter were $44.8 Million, up 5% Year-over-Year First Half 2025 Adjusted EBITDA of $22.5 Million, up 35% Year-over-Year and Representing 25% Margin of Revenues; Second Quarter Adjusted EBITDA of $10.9 Million, up 20% Year-over-YearRobust First Half Results and Positive Outlook for Remainder of...

August 13, 2025 1 EN
 PRESS RELEASE
Free
KMDA KAMADA

Kamada Announces FDA Approval of its Plasma Collection Center in Houst...

Kamada Announces FDA Approval of its Plasma Collection Center in Houston, Texas Houston Center Cleared to Commence Commercial Sales of Normal Source PlasmaState of the Art Facility has Annual Collection Capacity of Approximately 50,000 Liters of Plasma and an Estimated Annual Revenue Contribution of $8 Million to $10 Million at its Full CapacityCenter is Structured to Collect Normal Source Plasma and Specialty Plasma, such as Anti-Rabies and Anti-D; Anticipated to be One of the Largest Sites for Specialty Plasma Collection in the U.S. REHOVOT, Israel, and HOBOKEN, N.J., Aug. 11, 2025 (GL...

August 11, 2025 1 EN
 PRESS RELEASE
Free
KMDA KAMADA

Kamada to Announce Second Quarter and First Half Ended June 30, 2025 F...

Kamada to Announce Second Quarter and First Half Ended June 30, 2025 Financial Results on August 13, 2025 Company to Host Conference Call at 8:30am ET REHOVOT, Israel, and HOBOKEN, N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the second quarter and first half ended June 30, 2025, prior to the open of the U.S. f...

August 6, 2025 1 EN
 PRESS RELEASE
Free
KMDA KAMADA

Kamada Confirms Continuous Global Business Operations and Products Ava...

Kamada Confirms Continuous Global Business Operations and Products Availability Despite Recent Events in the Middle East REHOVOT, Israel and HOBOKEN, N.J., June 17, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that, while circumstances in the Middle East are evolving, the Company is continuing the operations and manufacturing at its Israeli facility focusing on business continuity, and ...

June 17, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch